Showing results (61-70 of 78) with videos related to
Sort By:
Pageof 8
Nature Communications|May 17, 2024
Ferritinophagy mediates adaptive resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancerHui Wang, Qianfan Hu, Yuzhong Chen, et al.Histopathology|April 18, 2023
Deep learning-based classification and spatial prognosis risk score on whole-slide images of lung adenocarcinomaHanlin Ding, Yipeng Feng, Xing Huang, et al.Cell Death & Disease|August 24, 2023
The super-enhancer-driven lncRNA LINC00880 acts as a scaffold between CDK1 and PRDX1 to sustain the malignance of lung adenocarcinomaYipeng Feng, Te Zhang, Zeyu Zhang, et al.Oncogenesis|October 10, 2022
Non-genetic stratification reveals epigenetic heterogeneity and identifies vulnerabilities of glycolysis addiction in lung adenocarcinoma subtypeXuming Song, Te Zhang, Hanlin Ding, et al.Journal for Immunotherapy of Cancer|June 27, 2023
Tobacco exposure primes the secretion of CCL21 positively associated with tertiary lymphoid structure and response to immunotherapyXuewen Yin, Hui Wang, Rutao Li, et al.Cancer Research|March 29, 2018
The Circular RNA circPRKCI Promotes Tumor Growth in Lung AdenocarcinomaMantang Qiu, Wenjia Xia, Rui Chen, et al.Journal of Hematology & Oncology|August 18, 2022
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathwayTe Zhang, Wenjie Xia, Xuming Song, et al.Cancer Science|February 12, 2025
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS<sup>G12C</sup> Inhibitors in Nonsmall Cell Lung CancerZehao Pan, Yuxian Qian, Yajing Wang, et al.Cancer Research|November 12, 2024
The circRNA cEMSY Induces Immunogenic Cell Death and Boosts Immunotherapy Efficacy in Lung AdenocarcinomaYijian Zhang, Xuming Song, Yipeng Feng, et al.Therapeutic Advances in Medical Oncology|November 29, 2023
Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapyYuzhong Chen, Yuanjian Shi, Hanlin Ding, et al.Pageof 8